Decallonne Brigitte, Snyers Bérengère, Elaut Nathalie, Peene Bernard, Verbeeck Julie, Van den Bruel Annick, De Schutter Harlinde
Endocrinology department, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Belgian Cancer Registry, Brussels, Belgium.
Arch Public Health. 2022 Mar 10;80(1):77. doi: 10.1186/s13690-022-00803-8.
Large scale observational studies are crucial to study thyroid cancer incidence and management, known to vary in time and place. Combining cancer registry data with other data sources enables execution of population-based studies, provided data sources are accurate. The objective was to compare thyroid tumour and treatment information between the available data sources in Belgium.
We performed a retrospective national population-based cohort study. All patients with thyroid cancer diagnosis in Belgium between 2009 and 2011 (N = 2659 patients) were retrieved from the Belgian Cancer Registry database, containing standard patient and tumour characteristics. Additionally, information was obtained from the following sources: a) detailed pathology reports b) the health insurance company database for reimbursed performed therapeutic acts (both available for N = 2400 patients) c) registration forms for performed and/or planned treatments at the time of the multidisciplinary team meeting (available for N = 1819 patients). More precisely, information was retrieved regarding characteristics of the tumour (histologic subtype, tumour size, lymph node status (source a)) and the treatment (thyroid surgery (a,b,c), lymph node dissection (a,b), postoperative administration of radioactive iodine (b,c)).
High concordance in histological cancer subtype (> 90%), tumour size (96.2%) and lymph node involvement (89.2%) categories was found between the cancer registry database and the pathology reports. Tumour subcategories (such as microcarcinoma, tumor ≤1 cm diameter) were more specified in the pathology reports. The therapeutic act of thyroid surgery as mentioned in the pathology reports and health insurance company database was concordant in 92.7%, while reports from multidisciplinary team meetings showed 88.5% of concordance with pathology reports and 86.1% with health insurance data. With regard to postoperative radioiodine administration, reports from multidisciplinary teams and health insurance data were concordant in 76.8%.
Combining registered and/or administrative data results in sufficiently accurate information to perform large scale observational studies on thyroid cancer in Belgium. However, thorough and continuous quality control and insight in strengths and limitations of each cancer data source is crucial.
大规模观察性研究对于研究甲状腺癌的发病率和治疗情况至关重要,已知其在时间和地点上存在差异。将癌症登记数据与其他数据源相结合能够开展基于人群的研究,前提是数据源准确无误。目的是对比比利时现有数据源之间的甲状腺肿瘤及治疗信息。
我们开展了一项基于全国人群的回顾性队列研究。从比利时癌症登记数据库中检索出2009年至2011年间在比利时被诊断为甲状腺癌的所有患者(N = 2659例患者),该数据库包含标准的患者和肿瘤特征。此外,信息还来源于以下几个方面:a)详细的病理报告;b)健康保险公司数据库中已报销的治疗行为(这两个来源均有N = 2400例患者的信息);c)多学科团队会诊时已实施和/或计划治疗的登记表(有N = 1819例患者的信息)。更确切地说,检索到了关于肿瘤特征(组织学亚型、肿瘤大小、淋巴结状态(来源a))和治疗(甲状腺手术(a、b、c)、淋巴结清扫(a、b)、术后放射性碘给药(b、c))的信息。
癌症登记数据库与病理报告之间在组织学癌症亚型(> 90%)、肿瘤大小(96.2%)和淋巴结受累情况(89.2%)类别上具有高度一致性。病理报告中肿瘤亚类别(如微癌、直径≤1 cm的肿瘤)更为具体。病理报告和健康保险公司数据库中提及的甲状腺手术治疗行为一致性为92.7%,而多学科团队会诊报告与病理报告的一致性为88.5%,与健康保险数据的一致性为86.1%。关于术后放射性碘给药,多学科团队报告与健康保险数据的一致性为76.8%。
整合登记数据和/或行政数据可得出足够准确的信息,以在比利时开展关于甲状腺癌的大规模观察性研究。然而,全面且持续的质量控制以及对每个癌症数据源优缺点的了解至关重要。